MicroRNA‑139 suppresses hepatocellular carcinoma cell proliferation and migration by directly targeting Topoisomerase I

Zhang,Pengfei; Yin,Jikai; Yuan,Lijuan; Wang,Qing; Du,Xilin; Dong,Rui; Wang,Chengguo; Bai,Qiangshan; Ji,Ling; Zhang,Guizhi; Lu,Jianguo

doi:10.3892/ol.2018.9746

MicroRNA‑139 suppresses hepatocellular carcinoma cell proliferation and migration by directly targeting Topoisomerase I

Authors:
- Pengfei Zhang
- Jikai Yin
- Lijuan Yuan
- Qing Wang
- Xilin Du
- Rui Dong
- Chengguo Wang
- Qiangshan Bai
- Ling Ji
- Guizhi Zhang
- Jianguo Lu
View Affiliations

Affiliations: Department of General Surgery, Tangdu Hospital of The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Department of Orthopedics, Tangdu Hospital of The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Department of Liver Disease, The Third People's Hospital, Linfen, Shanxi 041000, P.R. China
Published online on: November 22, 2018 https://doi.org/10.3892/ol.2018.9746
Pages: 1903-1913

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs (miRNAs) have been determined to be associated with cancer progression and metastasis. Mir‑139 is located on 11q13.4 and exhibits anti‑oncogenic and anti‑metastatic activity in human cancers. It is downregulated in various malignant tumor types. In the present study, the potential functions and targets of miR‑139 in hepatocellular carcinoma (HCC) were explored. Using a combinational analysis of four miRNA target prediction tools and biological experiments, it was determined that Topoisomerase I (TOP1) is a direct target of miR‑139 in HCC. Several traditional topoisomerase inhibitors have demonstrated anticancer activity, but their side effects outnumbered their anticancer potential. The present study determined that overexpression of miR‑139 significantly inhibits HCC cell proliferation (P<0.05) and migration (P<0.05), which is largely due to TOP1 downregulation. The present study indicated that miR‑139 exerts a tumor‑suppressive effect during hepatocarcinogenesis via the suppression of expression of TOP1; therefore, miR‑139 is a promising target for the treatment of HCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Carr BI: Hepatocellular carcinoma: Current management and future trends. Gastroenterology. 127:S218–S224. 2004. View Article : Google Scholar : PubMed/NCBI
3	Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
4	Garzon R, Calin GA and Croce CM: MicroRNAs in Cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
6	Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T and Shimotohno K: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 25:2537–2545. 2006. View Article : Google Scholar : PubMed/NCBI
7	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
8	Li T, Yin J, Yuan L, Wang S, Yang L, Du X and Lu J: Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival. Oncol Rep. 31:1699–1706. 2014. View Article : Google Scholar : PubMed/NCBI
9	Gu W, Li X and Wang J: miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway. Oncol Rep. 31:397–404. 2014. View Article : Google Scholar : PubMed/NCBI
10	Hua S, Lei L, Deng L, Weng X, Liu C, Qi X, Wang S, Zhang D, Zou X, Cao C, et al: miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1. Oncogene. 37:1624–1636. 2018. View Article : Google Scholar : PubMed/NCBI
11	Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K and Ng IO: The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 140:322–331. 2011. View Article : Google Scholar : PubMed/NCBI
12	Wang L, Liu M, Zhu H, Rong W, Wu F, An S, Liu F, Feng L, Wu J and Xu N: Identification of recurrence-related serum microRNAs in hepatocellular carcinoma following hepatectomy. Cancer Biol Ther. 16:1445–1452. 2015. View Article : Google Scholar : PubMed/NCBI
13	Qiu G, Lin Y, Zhang H and Wu D: miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2. Biochem Biophys Res Commun. 463:315–321. 2015. View Article : Google Scholar : PubMed/NCBI
14	Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB: Prediction of mammalian microRNA targets. Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
15	John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human MicroRNA targets. PLoS Biol. 2:e3632004. View Article : Google Scholar : PubMed/NCBI
16	Wong N and Wang X: miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
17	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
18	Ritchie W, Rasko JE and Flamant S: MicroRNA target prediction and validation. Adv Exp Med Biol. 774:39–53. 2013. View Article : Google Scholar : PubMed/NCBI
19	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
20	Xie X, Tan W, Chen B, Huang X, Peng C, Yan S, Yang L, Song C, Wang J, Zheng W, et al: Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer. Int J Cancer. 142:1901–1910. 2018. View Article : Google Scholar : PubMed/NCBI
21	Slattery ML, Lee FY, Pellatt AJ, Mullany LE, Stevens JR, Samowitz WS, Wolff RK and Herrick JS: Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype. Mod Pathol. 30:1152–1169. 2017. View Article : Google Scholar : PubMed/NCBI
22	Mannavola F, Tucci M, Felici C, Stucci S and Silvestris F: miRNAs in melanoma: A defined role in tumor progression and metastasis. Exp Rev Clin Immunol. 12:79–89. 2016. View Article : Google Scholar
23	Tian F, Li R, Chen Z, Shen Y, Lu J, Xie X and Ge Q: Differentially expressed miRNAs in tumor, adjacent, and normal tissues of lung adenocarcinoma. Biomed Res Int. 2016:14282712016. View Article : Google Scholar : PubMed/NCBI
24	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
25	Wang L, Zhang X, Jia LT, Hu SJ, Zhao J, Yang JD, Wen WH, Wang Z, Wang T, Zhao J, et al: c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology. 59:1850–1863. 2014. View Article : Google Scholar : PubMed/NCBI
26	Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J and Song E: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
27	Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q and Liu J: MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol. 84:320–330. 2012. View Article : Google Scholar : PubMed/NCBI
28	Krishnan K, Steptoe AL, Martin HC, Pattabiraman DR, Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Vlassov A, et al: miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA. 19:1767–1780. 2013. View Article : Google Scholar : PubMed/NCBI
29	Ashour ME, Atteya R and El-Khamisy SF: Topoisomerase-mediated chromosomal break repair: An emerging player in many games. Nat Rev Cancer. 15:137–151. 2015. View Article : Google Scholar : PubMed/NCBI
30	Stewart L, Redinbo MR, Qiu X, Hol WG and Champoux JJ: A model for the mechanism of human topoisomerase I. Science. 279:1534–1541. 1998. View Article : Google Scholar : PubMed/NCBI
31	Pommier Y, Sun Y, Huang SN and Nitiss JL: Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat Rev Mol Cell Biol. 17:703–721. 2016. View Article : Google Scholar : PubMed/NCBI
32	Kim N, Huang SN, Williams JS, Li YC, Clark AB, Cho JE, Kunkel TA, Pommier Y and Jinks-Robertson S: Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science. 332:1561–1564. 2011. View Article : Google Scholar : PubMed/NCBI
33	Larsen AK and Gobert C: DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde? Pathol Oncol Res. 5:171–178. 1999. View Article : Google Scholar : PubMed/NCBI
34	Rahman M, Jackson LK, Johnson WE, Li DY, Bild AH and Piccolo SR: Alternative preprocessing of RNA-sequencing data in the cancer genome atlas leads to improved analysis results. Bioinformatics. 31:3666–3672. 2015. View Article : Google Scholar : PubMed/NCBI
35	Kümler I, Balslev E, Stenvang J, Brünner N and Nielsen D: A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2-negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol. BMC Cancer. 15:782015. View Article : Google Scholar : PubMed/NCBI
36	Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 246:1046–1048. 1989. View Article : Google Scholar : PubMed/NCBI
37	Li M and Liu Y: Topoisomerase I in human disease pathogenesis and treatments. Genomics Proteomics Bioinformatics. 14:166–171. 2016. View Article : Google Scholar : PubMed/NCBI
38	Pommier Y: Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer. 6:789–802. 2006. View Article : Google Scholar : PubMed/NCBI
39	Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP and Krueger LJ: MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 67:9762–9770. 2007. View Article : Google Scholar : PubMed/NCBI
40	Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA and Jacks T: Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA. 105:3903–3908. 2008. View Article : Google Scholar : PubMed/NCBI